Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Aim: This study aimed to evaluate the association between the efficacy of durvalumab plus tremelimumab (Dur/Tre) and metabolic dysfunction-associated steatotic liver disease (MASLD) in patients with hepatocellular carcinoma (HCC).
Methods: A total of 239 patients with HCC who received Dur/Tre between March 2023 and October 2024 at multiple institutions in Japan were retrospectively analyzed. Patients were categorized into three groups based on underlying liver disease: viral-related HCC (n = 126), MASLD-related HCC (n = 30), and nonviral, non-MASLD HCC (n = 83).
Results: The overall response rates (ORR) were 17.5%, 16.7%, and 19.3% in viral-related HCC, MASLD-related HCC, and nonviral, non-MASLD HCC, respectively. The disease control rates (DCR) were 44.4%, 46.7%, and 51.8%, respectively. No significant differences in ORR (p = 0.6) or DCR (p = 0.9) were observed among the three groups. The median PFS was 3.7 months (95% CI, 2.8-4.9) in patients with viral-related HCC, 3.6 months (95% CI, 2.3-4.8) in patients with MASLD-related HCC, and 4.4 months (95% CI, 2.6-5.8) in patients with nonviral, non-MASLD HCC. The median OS was 14.4 months (95% CI, 9.8-NA) in patients with viral-related HCC and 11.0 months (95% CI, 6.4-NA) in patients with MASLD-related HCC, whereas it was not reached in patients with nonviral, non-MASLD HCC. No statistically significant differences in PFS (p = 1.0) and OS (p = 0.3) were found among the groups.
Conclusions: Dur/Tre showed comparable efficacy in MASLD-related HCC and other etiologies, warranting confirmation in larger cohorts.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/hepr.70023 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
From "Traditional" to "Trained" Immunity: Exploring the Novel Frontiers of Immunopathogenesis in the Progression of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD).
Biomedicines
August 2025
Hepatogastroenterology Division, Department of Precision Medicine, University of Campania Luigi Vanvitelli, 80138 Naples, Italy.
Metabolic dysfunction-associated steatotic liver disease (MASLD) has emerged as the most prevalent chronic hepatopathy and a leading precursor of hepatocellular carcinoma (HCC) worldwide. Initially attributed to insulin resistance (IR)-driven metabolic imbalance, recent insights highlight a multifactorial pathogenesis involving oxidative stress (OS), chronic inflammation, and immune dysregulation. The hepatic accumulation of free fatty acids (FFAs) initiates mitochondrial dysfunction and excessive reactive oxygen species (ROS) production, culminating in lipotoxic intermediates and mitochondrial DNA damage.
View Article and Find Full Text PDFA nationwide population-based cross-sectional time series study of hospitalized chronic liver disease burden in Thailand from 2017 to 2022.
Sci Rep
August 2025
Department of Epidemiology, Faculty of Medicine, Prince of Songkla University, Songkhla, Thailand.
Chronic liver disease (CLD) is a major global public health challenge due to its high morbidity and mortality. In Thailand, the burden of CLD remains underexplored despite its significant impact on healthcare systems. This study examines trends in hospitalizations, etiologies, and in-hospital mortality associated with CLD, including cirrhosis and hepatocellular carcinoma (HCC), from 2017 to 2022.
View Article and Find Full Text PDFNew Names, New Drugs, Better Outcomes in Steatotic Liver Disease.
Br J Hosp Med (Lond)
August 2025
Institute of Liver Studies, King's College Hospital, London, UK.
Steatotic liver disease (SLD) is a growing cause of chronic liver disease, with potential progression to cirrhosis, hepatocellular carcinoma (HCC), and liver failure. Previously known as non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH), new terminology, including metabolic-dysfunction associated steatotic liver disease (MASLD) and metabolic-dysfunction associated steatohepatitis (MASH), was introduced to improve diagnostic clarity and reduce stigmatization. MASLD is now recognized as the hepatic manifestation of the metabolic syndrome and is the most common cause of liver disease in the UK, affecting up to 20% of adults.
View Article and Find Full Text PDFAssociation of Metabolic-Associated Steatotic Liver Disease With Clinical Outcomes of Durvalumab and Tremelimumab in Advanced Hepatocellular Carcinoma Patients: A Multicenter Study.
Hepatol Res
August 2025
Department of Clinical Research, NHO Takasaki General Medical Center, Takasaki, Japan.
Aim: This study aimed to evaluate the association between the efficacy of durvalumab plus tremelimumab (Dur/Tre) and metabolic dysfunction-associated steatotic liver disease (MASLD) in patients with hepatocellular carcinoma (HCC).
Methods: A total of 239 patients with HCC who received Dur/Tre between March 2023 and October 2024 at multiple institutions in Japan were retrospectively analyzed. Patients were categorized into three groups based on underlying liver disease: viral-related HCC (n = 126), MASLD-related HCC (n = 30), and nonviral, non-MASLD HCC (n = 83).
Genetic variants underlying precancerous conditions of hepatocellular carcinoma.
Int J Cancer
August 2025
Graduate Institute of Metabolism and Obesity Sciences, Taipei Medical University, Taipei, Taiwan.
Hepatocellular carcinoma (HCC) is the most common form of liver cancer, accounting for 80% of cases worldwide. While chronic hepatitis B and C infections remain primary risk factors, emerging evidence highlights the increasing contributions of metabolic dysfunction-associated steatotic liver disease (MASLD) and alcohol-associated liver disease (ALD) to HCC development. Genetic predispositions play a crucial role in modulating individual susceptibility to HCC, particularly through variants affecting viral persistence, lipid metabolism, and fibrogenesis.
View Article and Find Full Text PDF